Company
Novavax, Inc.
NASDAQ:NVAX
Novavax is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology.
32 stories · page 1 of 2
Novavax slumps after halving its sales forecast amid global supply glut and low vaccine demand
The US biotech company now expects total revenues for 2022 to be in the range of US$2bn-US$2.3bn, down from its prior forecast of US$4bn-US$5bn
Novavax Covid-19 vaccine recommended for US approval by FDA advisory panel
If approved by the FDA, the Novavax shot would become the first protein-based Covid-19 vaccine available in the US
Archive
US stock flirt with new record highs as investors shrug off Omicron concern
US stock indexes grew after figures showed that consumer-spending growth cooled last month
Novavax says COVID-19 vaccine 90% effective, also tested in combination with influenza jab
The UK has booked 60mln doses of the jab, though Novavax has yet to file documents for approval
Novavax expands late-stage UK trial for COVID-19 vaccine candidate to 15,000 volunteers
So far the firm has enrolled 5,500 participants to date and expects to complete the recruitment by the end of November
Novavax to present on COVID-19 vaccine candidate this week
The company is attending the 2020 World Vaccine Congress Washington scheduled for this week
Novavax to start late-stage trials for COVID-19 vaccine in UK
The US firm will enrol up to 10,000 participants aged 18-84 over the next six weeks
Archive
The week in coronavirus: Westminster wants people back to work, low-income people paid to quarantine, more job cuts from Gatwick Airport and others…
A look at the week's major news regarding the pandemic
Novavax expects to submit COVID-19 vaccine before US authorities in December
Data from the second phase of clinical trials is expected in the fourth quarter of 2020
Novavax to provide 60mln COVID-19 vaccine doses to UK government
AstraZeneca also announced plans to make 400mln doses of a COVID-19 vaccine for Latin American countries in early 2021